XML 50 R27.htm IDEA: XBRL DOCUMENT
v3.25.2

Fair Value Measurements (Tables) | 6 Months Ended
--- | ---
Jun. 29, 2025
Fair Value Disclosures [Abstract] |
Summary of Derivative Activity | The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 29, 2025 and June 30, 2024, net of tax:
| June 29, 2025 |  | June 30, 2024
(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense |  | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense
The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Hedged items | $— | — | — | 52 | — |  | — | — | — | (53) | —
Derivatives designated as hedging instruments | — | — | — | (52) | — |  | — | — | — | 53 | —
Gain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | — | — | — | 48 | — |  | — | — | — | 33 | —
Amount of gain or (loss) recognized in AOCI | — | — | — | 48 | — |  | — | — | — | 33 | —
Gain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | 2 | (132) | (16) | — | (3) |  | (1) | 94 | 8 | — | 3
Amount of gain or (loss) recognized in AOCI | 11 | 466 | (72) | — | (29) |  | 2 | 66 | 11 | — | 1
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | — | — | — | 76 | — |  | — | — | — | 42 | —
Amount of gain or (loss) recognized in AOCI | $— | — | — | 108 | — |  | — | — | — | (38) | —
The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 29, 2025 and June 30, 2024, net of tax:
| June 29, 2025 |  | June 30, 2024
(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense |  | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income) Expense
The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Hedged items | $— | — | — | 240 | — |  | — | — | — | (45) | —
Derivatives designated as hedging instruments | — | — | — | (240) | — |  | — | — | — | 45 | —
Gain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | — | — | — | 98 | — |  | — | — | — | 67 | —
Amount of gain or (loss) recognized in AOCI | — | — | — | 98 | — |  | — | — | — | 67 | —
Gain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | 1 | (122) | (15) | — | (3) |  | — | 259 | 12 | — | 1
Amount of gain or (loss) recognized in AOCI | 14 | 571 | (108) | — | (40) |  | (1) | 47 | 33 | — | 5
Cross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  |  |
Amount of gain or (loss) reclassified from AOCI into income | — | — | — | 158 | — |  | — | — | — | 91 | —
Amount of gain or (loss) recognized in AOCI | $— | — | — | 673 | — |  | — | — | — | (243) | —
The following table is the effect of net investment hedges for the fiscal second quarters ended in 2025 and 2024:
|  | Gain/(Loss) Recognized In Accumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income |  | Gain/(Loss) Reclassified From Accumulated OCI Into Income
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  |  |  | June 29, 2025 |  | June 30, 2024
Debt |  | $(803) |  | 46 |  | Interest (income) expense |  | — |  | —
Cross Currency interest rate swaps |  | $(700) |  | 92 |  | Interest (income) expense |  | — |  | —
The following table is the effect of net investment hedges for the fiscal six months ended in 2025 and 2024
|  | Gain/(Loss) Recognized In Accumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated OCI Into Income |  | Gain/(Loss) Reclassified From Accumulated OCI Into Income
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  |  |  | June 29, 2025 |  | June 30, 2024
Debt |  | $(1,119) |  | 130 |  | Interest (income) expense |  | — |  | —
Cross Currency interest rate swaps |  | $140 |  | 820 |  | Interest (income) expense |  | — |  | —
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet | As of June 29, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions) |  | June 29, 2025 |  | December 29, 2024 |  | June 29, 2025 |  | December 29, 2024
Long-term Debt |  | $8,209 |  | 7,935 |  | (820) |  | (1,132)
Schedule of Effect of Derivatives not Designated as Hedging Instruments | The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended and fiscal six months ended 2025 and 2024:
|  |  |  | Gain/(Loss) Recognized In Income on Derivative |  | Gain/(Loss) Recognized In Income on Derivative
(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
Derivatives Not Designated as Hedging Instruments |  |  |  | June 29, 2025 |  | June 30, 2024 |  | June 29, 2025 |  | June 30, 2024
Foreign Exchange Contracts |  | Other (income) expense |  | $(19) |  | 20 |  | 43 |  | 45
Summary of Activity Related to Equity Investments | The following table is a summary of the activity related to equity investments:
|  | December 29, 2024 |  |  |  |  |  | June 29, 2025
(Dollars in Millions) |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income (1) |  | (Sales)/ Purchases/Other (2) |  | Carrying Value |  | Non Current Other Assets
Equity Investments with readily determinable value |  | $451 |  | (57) |  | 59 |  | 453 |  | 453
Equity Investments without readily determinable value |  | $773 |  | (26) |  | 76 |  | 823 |  | 823
(1)Recorded in Other (income)/expense, net (2)Other includes impact of currency
Financial Assets and Liabilities at Fair Value | The Company’s significant financial assets and liabilities measured at fair value as of June 29, 2025 and December 29, 2024 were as follows:
|  | June 29, 2025 |  | December 29, 2024
(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)
Derivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | $— |  | 1,006 |  | — |  | 1,006 |  | 660
Interest rate contracts(2) |  | — |  | 431 |  | — |  | 431 |  | 1,484
Total |  | — |  | 1,437 |  | — |  | 1,437 |  | 2,144
Liabilities: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  | 774 |  | — |  | 774 |  | 794
Interest rate contracts(2) |  | — |  | 6,234 |  | — |  | 6,234 |  | 3,753
Total |  | — |  | 7,008 |  | — |  | 7,008 |  | 4,547
Derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  | 57 |  | — |  | 57 |  | 50
Liabilities: |  |  |  |  |  |  |  |  |  |
Forward foreign exchange contracts |  | — |  | 72 |  | — |  | 72 |  | 17
Other Investments: |  |  |  |  |  |  |  |  |  |
Equity investments(3) |  | 453 |  | — |  | — |  | 453 |  | 451
Debt securities(4) |  | — |  | 2,094 |  | — |  | 2,094 |  | 7,216
Other Liabilities: |  |  |  |  |  |  |  |  |  |
Contingent consideration(5) |  | $— |  | — |  | 1,157 |  | 1,157 |  | 1,217
Gross to Net Derivative Reconciliation |  | June 29, 2025 |  | December 29, 2024
(Dollars in Millions) |  |  |  |
Total Gross Assets |  | $1,494 |  | 2,194
Credit Support Agreement (CSA) |  | (1,471) |  | (2,172)
Total Net Asset |  | 23 |  | 22
Total Gross Liabilities |  | 7,080 |  | 4,564
Credit Support Agreement (CSA) |  | (6,666) |  | (4,412)
Total Net Liabilities |  | $414 |  | 152
Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 29, 2025 and June 30, 2024 is as follows:
|  | June 29, 2025 |  | June 30, 2024
(Dollars in Millions) |  |  |  |
Beginning Balance |  | $1,217 |  | 1,092
Changes in estimated fair value(6) |  | (60) |  | 44
Additions |  | — |  | 112
Payments |  | — |  | —
Ending Balance |  | $1,157 |  | 1,248
(1)2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3. (2)Includes cross currency interest rate swaps and interest rate swaps. (3)Classified as non-current other assets. (4)Classified within cash equivalents and current marketable securities. (5)Includes $1,107 million and $1,217 million classified as non-current other liabilities as of June 29, 2025 and December 29, 2024, respectively. Includes $50 million classified as current liabilities as of June 29, 2025. (6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
Marketable Securities | The Company's cash, cash equivalents and current marketable securities as of June 29, 2025 comprised:
(Dollars in Millions) | Carrying Amount |  | Unrealized Gain |  |  |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities
Cash | $3,246 |  | — |  |  |  | 3,246 |  | 3,246 |  | —
U.S. reverse repurchase agreements | 8,040 |  | — |  |  |  | 8,040 |  | 8,040 |  | —
Money market funds | 4,637 |  | — |  |  |  | 4,637 |  | 4,637 |  | —
Time deposits(1) | 863 |  | — |  |  |  | 863 |  | 863 |  | —
Subtotal | 16,786 |  | — |  |  |  | 16,786 |  | 16,786 |  | —
U.S. Gov’t securities | 1,673 |  | — |  |  |  | 1,673 |  | 1,659 |  | 14
Other sovereign securities | 193 |  | — |  |  |  | 193 |  | 94 |  | 99
Corporate debt securities | 228 |  | — |  |  |  | 228 |  | 38 |  | 190
Subtotal available for sale debt(2) | $2,094 |  | — |  |  |  | 2,094 |  | 1,791 |  | 303
Total cash, cash equivalents and current marketable securities | $18,880 |  | — |  |  |  | 18,880 |  | 18,577 |  | 303
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities | The contractual maturities of the available for sale securities as of June 29, 2025 are as follows:
(Dollars in Millions) |  | Cost Basis |  | Fair Value
Due within one year |  | $2,075 |  | 2,075
Due after one year through five years |  | 19 |  | 19
Due after five years through ten years |  | — |  | —
Total debt securities |  | $2,094 |  | 2,094
Financial Liabilities not Measured at Fair Value | Financial instruments not measured at fair value The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 29, 2025:
(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value
Financial Liabilities |  |  |  |
Current Debt |  | $11,526 |  | 11,495
Non-Current Debt |  |  |  |
2.95% Notes due 2027 |  | 950 |  | 984
0.95% Notes due 2027 |  | 1,478 |  | 1,410
4.50% Notes due 2027(1) |  | 749 |  | 757
2.90% Notes due 2028 |  | 1,498 |  | 1,460
1.150% Notes due 2028 (750MM Euro 1.1704) |  | 881 |  | 843
4.55% Notes due 2028(1) |  | 748 |  | 762
4.80% Notes due 2029 |  | 1,146 |  | 1,181
6.95% Notes due 2029 |  | 299 |  | 334
2.70% Notes due 2029 (600MM Euro 1.1704)(1) |  | 706 |  | 708
1.30% Notes due 2030 |  | 1,676 |  | 1,521
4.70% Notes due 2030(1) |  | 995 |  | 1,022
4.90% Notes due 2031 |  | 1,146 |  | 1,189
3.20% Notes due 2032 (700MM Euro 1.1704) |  | 821 |  | 834
4.85% Notes due 2032(1) |  | 1,242 |  | 1,281
4.95% Notes due 2033 |  | 499 |  | 517
4.375% Notes due 2033 |  | 853 |  | 847
3.050% Notes due 2033 ( 700MM Euro 1.1704)(1) |  | 822 |  | 822
4.95% Notes due 2034 |  | 847 |  | 880
1.650% Notes due 2035 (1.5B Euro 1.1704) |  | 1,756 |  | 1,528
5.00% Notes due 2035(1) |  | 1,244 |  | 1,282
3.35% Notes due 2036 (800MM Euro 1.1704) |  | 937 |  | 939
3.587% Notes due 2036 |  | 905 |  | 902
5.95% Notes due 2037 |  | 994 |  | 1,103
3.625% Notes due 2037 |  | 1,396 |  | 1,334
3.350% Notes due 2037 (1.0B Euro 1.1704)(1) |  | 1,175 |  | 1,160
3.40% Notes due 2038 |  | 993 |  | 857
5.85% Notes due 2038 |  | 697 |  | 761
4.50% Notes due 2040 |  | 542 |  | 523
2.10% Notes due 2040 |  | 885 |  | 684
4.85% Notes due 2041 |  | 298 |  | 291
4.50% Notes due 2043 |  | 496 |  | 459
3.55% Notes due 2044 (1.0B Euro 1.1704) |  | 1,103 |  | 1,135
3.60% Notes due 2045 (700MM Euro 1.1704)(1) |  | 819 |  | 792
3.73% Notes due 2046 |  | 1,979 |  | 1,592
3.75% Notes due 2047 |  | 863 |  | 798
3.50% Notes due 2048 |  | 744 |  | 567
2.25% Notes due 2050 |  | 851 |  | 580
5.25% Notes due 2054 |  | 843 |  | 837
3.70% Notes due 2055 (1.0B Euro 1.1704)(1) |  | 1,172 |  | 1,118
2.45% Notes due 2060 |  | 1,102 |  | 694
Other |  | 85 |  | 88
Total Non-Current Debt |  | $39,235 |  | 37,376
(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cash, cash equivalent, and investment. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CC -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 182 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details
Name: | us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CC -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration